Market Place
Sourcing Support
All News #Library
Biotech
BioLineRx, Hemispherian Dose First Patient in GBM Study
28 Apr 2026 //
PR NEWSWIRE
BiolineRx Starts Phase 1/2A Trial Of GLIX1 For Glioblastoma (GBM)
26 Mar 2026 //
PR NEWSWIRE
BioLinerx To Report 2025 Annual Results On March 23, 2026
16 Mar 2026 //
PR NEWSWIRE
Biolinerx Unveils Q3 2025 Financials And Corporate Update
24 Nov 2025 //
PR NEWSWIRE
Hemispherian Secures GLIX1 Patent for Solid Tumors
19 Nov 2025 //
BUSINESSWIRE
Biolinerx, Hemispherian As Form Joint Venture For Glix1
29 Sep 2025 //
PR NEWSWIRE
BioLineRx to Present New Phase 2 Data on Motixafortide at ASCO
30 May 2025 //
PR NEWSWIRE
BioLineRx Reports 2024 Financial Results and Corporate Update
31 Mar 2025 //
PR NEWSWIRE
BioLineRx & Ayrmid License Agreement for APHEXDA Commercialization
21 Nov 2024 //
PR NEWSWIRE
BioLineRx to Present Motixafortide Data for Sickle Cell at ASH 2024
05 Nov 2024 //
PR NEWSWIRE
BioLineRx Announces Clinical Trial Pact With St Jude`s For Motixafortide
30 May 2024 //
PR NEWSWIRE
BioLineRx Accesses Second Tranche of $20M Financing
10 Apr 2024 //
PR NEWSWIRE
BioLineRx Announces First Patient Dosed in Ph 2 Trial Evaluating Motixafortide
28 Feb 2024 //
PR NEWSWIRE
BioLineRx Announces First Patient Dosed in Ph 1 Trial Evaluating Motixafortide
21 Dec 2023 //
PR NEWSWIRE
BioLineRx Entered Agreement with Motixafortide in Asia, Advised by MSQ Ventures
31 Oct 2023 //
PR NEWSWIRE
BioLineRx Announces Data from Phase 2 Clinical Trial with Motixafortide
28 Sep 2023 //
PR NEWSWIRE
BioLineRx Announces Acceptance of Presentation on Ph 2 Trial with Motixafortide
19 Sep 2023 //
PR NEWSWIRE
BioLineRx’s Aphexda approved to aid stem cell transplants
12 Sep 2023 //
ENDPTS
BioLineRx Announces FDA Approval of APHEXDA for Hematopoietic Stem Cells
11 Sep 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.